Cerity Partners LLC Invests $654,000 in Janux Therapeutics, Inc. (NASDAQ:JANX)

Cerity Partners LLC bought a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 60,933 shares of the company's stock, valued at approximately $654,000. Cerity Partners LLC owned about 0.13% of Janux Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in JANX. Barclays PLC lifted its holdings in shares of Janux Therapeutics by 227.1% during the 3rd quarter. Barclays PLC now owns 17,922 shares of the company's stock worth $181,000 after acquiring an additional 12,443 shares during the period. FMR LLC raised its stake in Janux Therapeutics by 25.5% during the third quarter. FMR LLC now owns 6,351,322 shares of the company's stock worth $64,021,000 after acquiring an additional 1,288,526 shares in the last quarter. Old Well Partners LLC bought a new position in shares of Janux Therapeutics during the third quarter valued at $104,000. Corton Capital Inc. bought a new position in Janux Therapeutics during the 3rd quarter valued at about $111,000. Finally, Adage Capital Partners GP L.L.C. increased its holdings in shares of Janux Therapeutics by 27.8% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company's stock worth $11,592,000 after buying an additional 250,000 shares in the last quarter. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Price Performance

NASDAQ:JANX traded down $1.57 on Wednesday, hitting $48.21. 580,038 shares of the company's stock were exchanged, compared to its average volume of 756,076. The company has a market cap of $2.49 billion, a P/E ratio of -35.98 and a beta of 4.18. The firm has a 50-day moving average price of $37.62 and a 200-day moving average price of $18.97. Janux Therapeutics, Inc. has a 52 week low of $5.65 and a 52 week high of $58.69.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.12. The firm had revenue of $2.46 million during the quarter, compared to analysts' expectations of $0.98 million. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. On average, research analysts expect that Janux Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Bank of America raised their target price on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, March 13th. Wedbush reaffirmed an "outperform" rating and set a $53.00 target price on shares of Janux Therapeutics in a report on Monday, March 11th. BTIG Research started coverage on Janux Therapeutics in a research note on Thursday, March 21st. They set a "buy" rating and a $62.00 price objective for the company. Finally, Cantor Fitzgerald initiated coverage on Janux Therapeutics in a report on Wednesday, March 20th. They set an "overweight" rating and a $100.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $61.33.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.